A new study recently published in the Chinese Medical Journal revealed that a 6-month warfarin treatment might not be sufficient as an effective therapy for patients with pulmonary embolism complicated by obstructive sleep apnea hypopnea syndrome (OSAHS).
The goal of the study was to assess whether routine warfarin treatment for 6 months would be effective enough in individuals with pulmonary embolism aggravated by OSAHS.
The team analyzed 97 patients with pulmonary embolism, from whom 32 had OSAHS. Warfarin treatment was administered for 6 months and all the patients were followed-up for 18 months.
Researchers found that OSAHS patients required a higher warfarin dose in comparison to patients without OSAHS (4.73 mg and 3.61 mg, respectively).
After the 6-month warfarin therapy, researchers found that OSAHS patients had a higher recurrence of pulmonary embolism in comparison to patients without OSAHS (21.43% and 6.78%, respectively).
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive